Sign In
Gift Card Activation
Create Account
Forgot Password?
Temporary Code
Save
The European Society of Gynaecological Oncology |
ESGO.org
Home
Webinars
Surgical Videos
eCourses
Events
Topics
Publications
Guidelines
ESGO GO Curriculum
Newly published
Free Content
Sponsored Section
Search
Loading
Navbar input
WAIT FOR SUGGESTIONS BY CATEGORY
OR CONTINUE TYPING IN YOUR KEYWORDS
ENTER ONE OR MULTIPLE KEYWORDS &
PRESS THE SEARCH BUTTON
From
To
Search
Favorites
Advanced
Minimize
More ▾
Less ▸
Clear
Protected by US Patents
For full functionality of this site it is necessary to enable JavaScript. Here are the
instructions how to enable JavaScript in your web browser
.
Defining Notch signaling mechanisms associated with the cardiovascular phenotypes of Alagille Syndrome
ESGO eAcademy, Shelby Thomas, 343914
Should we screen for ovarian cancer in high-risk women - current status and future strategies
ESGO eAcademy, Usha Menon, 340966
Population-based genetic testing for cancer prevention
ESGO eAcademy, Ranjit Manchanda, 340965
Management of VaIN
ESGO eAcademy, Vesna Kesic, 343725
Adherence to European ovarian cancer guidelines and impact on survival: a French multicenter study (FRANCOGYN)
ESGO eAcademy, Floriane Jochum, 343747
ERAS protocols in gynaecological oncology. Should we include thoracic epidural analgesia?
ESGO eAcademy, Anastasios Pandraklakis, 343745
European enhanced recovery after surgery (ERAS) gynecological oncology survey: Current state of perioperative practice
ESGO eAcademy, Natalia R. Gómez-Hidalgo, 343743
Short- and long-term urological complications after surgery for early-stage cervical cancer
ESGO eAcademy, María Tiermes Marina Martín, 343741
Advanced gynecological cancer: Quality of life one year after diagnosis
ESGO eAcademy, Björg Jónsdóttir, 343739
Loss of ovarian function in young patients with cancer: prognostic model
ESGO eAcademy, Raffaella Cioffi, 343737
Pelvic exenteration for vulvar cancer: Postoperative morbidity and oncologic outcome - A single center retrospective study
ESGO eAcademy, Hanna Valstad, 343735
Management of VIN
ESGO eAcademy, Mario Preti, 343724
ESGO, ISSVD, EFC and ECSVD Consensus statement: Pre-invasive vulvar and vaginal lesions
ESGO eAcademy, Murat Gultekin, 343723
Tumor cell dissemination is independent from endometrial carcinoma molecular subtypes
ESGO eAcademy, Lea Volmer, 343733
Indocyanine green to assess vascularity of ileal conduit anastomosis during pelvic exenteration for recurrent/persistent gynecological cancer
ESGO eAcademy, Nicolo Bizzarri, 343731
Evolution of terminology and classification of VIN
ESGO eAcademy, Jacob Bornstein, 342915
Palbociclib and metformin show anticancer efficacy in high grade serous ovarian cancer
ESGO eAcademy, Irina Tsibulak, 343729
Preinvasive disease of vulva and vagina - Q&A
ESGO eAcademy, Faculty / Presenters, 343727
Novel non-surgical prevention strategies in high-risk women
ESGO eAcademy, Susan Domchek, 340964
Reconstructive surgery in the surgical management of VIN and VaIN
ESGO eAcademy, Pawel Knapp, 343726
Gestational Trophoblastic Disease – The need to collaborate beyond country borders - Q&A
ESGO eAcademy, Faculty / Presenters, 340953
Scientific session 14: Regional challenges in gynaecological cancer and access to care - Q&A
ESGO eAcademy, Nadeem R. Abu-Rustum, 340960
Establishing a new GTD centre: a Serbian experience
ESGO eAcademy, Vesna Kesic, 340952
Challenges in gynaecological cancer care and access in developing nations
ESGO eAcademy, Jalid Sehouli, 340959
Personalised treatment in gynaecological sarcoma
ESGO eAcademy, Isabelle Ray-Coquard, 340945
Hot news in GTD management through international collaboration
ESGO eAcademy, Michael Seckl, 340951
Rare variants of ovarian cancer
ESGO eAcademy, Elena Ioanna Braicu, 340944
International networks for rare tumours, what the EOTTD can contribute to care and education
ESGO eAcademy, Christianne Lok, 340950
Rare gynaecological tumours: How developments in pathobiology help treatment and research - Q&A
ESGO eAcademy, Faculty / Presenters, 343722
Scientific session 13: Rare gynaecological tumours: How developments in pathobiology help treatment and research
ESGO eAcademy, Faculty / Presenters, 340939
Rare variants of endometrial carcinoma
ESGO eAcademy, Xavier Matias-Guiu, 340943
Elimination of Cervical Cancer European Experience
ESGO eAcademy, Artem Stepanyan, 340958
State of the art 11: Does the tumour microenvironment hold the key to the success of immunotherapy? - Q&A
ESGO eAcademy, Faculty / Presenters, 340932
Updates on combinatorial approaches in ovarian cancer immunotherapy
ESGO eAcademy, Christian Marth, 340931
Resection of the upper paracervical lymphovascular tissue should be a part of a pelvic sentinel lymph node algorithm in early stage cervical cancer
ESGO eAcademy, Oscar Lührs, 343720
SENTIX - Accuracy of preoperative local staging in the Sentix trial (CEEGOG-CX01; ENGOT-CX2; NCT02494063)
ESGO eAcademy, Jaroslav Klat, 343718
The impact of micrometastases in cervical cancer patients - a retrospective study of the SCCAN (Surveillance in Cervical CANcer) project
ESGO eAcademy, Lukas Dostalek, 343716
Findings and outcomes in a post-vaccination cohort of young women under 25 years attending a tertiary colposcopy service
ESGO eAcademy, Cheryl Yim, 343714
Sentinel Lymph Node Mapping in Early-Stage Cervical Cancer – A National Prospective Multicentre Study (SENTIREC Trial)
ESGO eAcademy, Sara Sponholtz, 343712
Immunological configuration of ovarian carcinoma: Impact on disease outcome and response to immunotherapy
ESGO eAcademy, Jitka Palich Fucikova, 343708
Debate 3: Management of patients with "intermediate risk" cervical cancer
ESGO eAcademy, Faculty / Presenters, 340935
Debate 3: Management of patients with "intermediate risk" cervical cancer
ESGO eAcademy, Alexandra Taylor, 340938
State of the art 9: Are we reaching the safety limit for fertility preservation in gynaecologic malignancies? - Q&A
ESGO eAcademy, Faculty / Presenters, 340914
Prevention of burn-out for health care providers
ESGO eAcademy, Vesna Kesic, 340925
Cancer is a “WE-disease” – family and partner involvement as the main caregivers
ESGO eAcademy, Annette Hasenburg, 340924
Could we preserve fertility with any myometrial infiltration in endometrial cancer?
ESGO eAcademy, Alexandros Rodolakis, 340913
Empowering life for patients
ESGO eAcademy, Joachim Weis, 340923
Scientific session 12: Empowering life - Q&A
ESGO eAcademy, Faculty / Presenters, 343707
Brachytherapy in gynaecological tumours (cervical, endometrial, vaginal) Q&A
ESGO eAcademy, Faculty / Presenters, 343706
Endometrial cancer. Don´t forget curative, brachytherapy-based radiotherapy when surgery is contraindicated
ESGO eAcademy, Elzbieta van der Steen-Banasik, 343705
Image-guided radiotherapy for primary vaginal cancer: Impact on disease outcome and morbidity
ESGO eAcademy, Lars Fokdal, 343704
Cervical cancer: Image-guided external beam radiotherapy and brachytherapy
ESGO eAcademy, Remi Nout, 343703
Fertility preservation in ovarian cancer: safety boundaries
ESGO eAcademy, Ignacio Zapardiel, 340912
Should neoadjuvant chemotherapy be a standard in fertility sparing treatment of cervical cancer?
ESGO eAcademy, Michael Halaska, 340911
Scientific session 11: Selection of patients with relapsed ovarian cancer for surgery - Q&A
ESGO eAcademy, Faculty / Presenters, 340888
Tumour board 3: Borderline ovarian tumours: Individualising patient management - Discussion
ESGO eAcademy, Faculty / Presenters, 340906
Surgery in recurrent ovarian cancer - Improving selection process by integrating molecular biology
ESGO eAcademy, Nicole Concin, 340887
Serous borderline tumour/ low-grade serous carcinoma: oncological treatments (what and when)
ESGO eAcademy, Gourley Charlie, 340905
Surgery in recurrent ovarian cancer - Improving selection process by integrating pre-operative imaging & laparoscopy into the clinical algorithm
ESGO eAcademy, Anna Fagotti, 340886
Abdominal wall complications after GynOnc surgery - treatment and management
ESGO eAcademy, Luis Chiva, 340896
Serous borderline tumours: does implant type matter and limits of fertility-preserving surgery
ESGO eAcademy, Philippe Morice, 340904
Miscellaneous complications in GynOnc surgery - interactive workshop with case reports: diagnosis, treatment and management
ESGO eAcademy, Beyhan Ataseven, 340895
What is the State-of-the-Art: RCTs in surgery for recurrent Ovarian Cancer
ESGO eAcademy, Andreas du Bois, 340885
Pathology of borderline ovarian tumours: more than one disease
ESGO eAcademy, Glenn McCluggage, 340903
Video abstract 3 - Laterally extended pelvic resection with complete resection of ureter and nephrectomy
ESGO eAcademy, Michal Zikan, 340880
Video abstract 2 - ID 848: Indocyanine green to assess vascularity of Bricker ileal conduit anastomosis during pelvic exenteration for recurrent cervical cancer
ESGO eAcademy, Nicolo Bizzarri, 340879
Video abstract 1 - ID 1021: V-Y flap reconstruction for vulvar cancer recurrence after primary radiotherapy
ESGO eAcademy, Sergi Fernandez, 340878
Pelvic exenteration-Out of the box
ESGO eAcademy, Gwenael Ferron, 340877
Pelvic reconstruction
ESGO eAcademy, Cagatay Taskiran, 340876
Major advances in gynaecological cancers 2021. Improving the standard of care: "More is NOT better!" -
ESGO eAcademy, Antonio Gonzalez Martin, 343691
Immunotherapy: New era in the management of endometrial and cervical cancers
ESGO eAcademy, Mansoor Raza Mirza, 343692
Focus on novel therapy in gynaecological cancers
ESGO eAcademy, Domenica Lorusso, 343693
State of the art 8: Major advances in gynaecological cancers 2021 - Discussion
ESGO eAcademy, Faculty / Presenters, 343694
Molecular profiling of NSMP high-risk endometrial cancers of the PORTEC-3 trial – prognostic refinement and druggable targets
ESGO eAcademy, Lisa Vermij, 343697
Molecular classification of endometrial carcinoma substantially changing risk-assessment: Results from a european multicentre initiative.
ESGO eAcademy, Stefan Kommoss, 343698
Dostarlimab in advanced/recurrent mismatch repair deficient/microsatellite instability high or proficient/stable endometrial cancer: the GARNET study
ESGO eAcademy, Ana Oaknin, 343699
Real-world patterns of care and outcomes in patients with microsatellite-instability high tumors in advanced endometrial cancer in the United States
ESGO eAcademy, Prabhu Vimalanand, 343700
Best oral - late breaking abstracts 2 - Q&A
ESGO eAcademy, Faculty / Presenters, 343702
Technique of the pelvic exenteration
ESGO eAcademy, Francesco Raspagliesi, 340875
Perspectives on robotic assisted surgery in Gynecology Oncology during Covid times
ESGO eAcademy, Faculty / Presenters, 340864
Tumour board 2: Management of gynaecological sarcomas - Q&A
ESGO eAcademy, Faculty / Presenters, 340853
Scientific session 10: Immune checkpoint inhibitors- ready for the prime time in endometrial and cervical cancers? - Discussion
ESGO eAcademy, Faculty / Presenters, 340845
ERAS and impact of evidenced-based medicine in modern ovarian cancer surgical care
ESGO eAcademy, Pedro Ramirez, 340860
Adjuvant treatment of uterine sarcomas and management of metastatic disease
ESGO eAcademy, Ronnie Shapira-Frommer, 340852
How to improve immunotherapy strategies in uterine cancers: combinations and beyond
ESGO eAcademy, Faculty / Presenters, 340844
Role of immunotherapy in advanced and recurrent cervical cancer
ESGO eAcademy, Domenica Lorusso, 350673
Hot topics of the gyanecological oncologist: summary of recommendations
ESGO eAcademy, Dimitrios Haidopoulos, 340859
Diagnosis and surgical treatment of endometrial stromal sarcoma and uterine adenosarcoma - Anything new?
ESGO eAcademy, Mehmet Mutlu Meydanli, 340851
Role of immunotherapy in advanced and recurrent cervical cancer
ESGO eAcademy, Domenica Lorusso, 340843
Overview of the new ESGO perioperative guidelines for ovarian cancer surgery
ESGO eAcademy, Christina Fotopoulou, 340858
How to diagnose and manage uterine leiomyosarcoma?
ESGO eAcademy, Frederic Amant, 340850
Role of immunotherapy in advanced and recurrent endometrial cancer
ESGO eAcademy, Ana Oaknin, 350672
Antibody Drug Conjugates in Treating Recurrent Ovarian Cancer: The Next Generation – A Focus on NaPi2b
ESGO eAcademy, Faculty / Presenters, 340834
State of the art 6: SLN in gynaecological tumours (State of the art 2021 and next steps) - Discussion
ESGO eAcademy, Faculty / Presenters, 340819
Scientific session 9: PARP resistance - how might this be avoided or overcome? - Discussion
ESGO eAcademy, Faculty / Presenters, 340833
How we can discuss palliation with our patients
ESGO eAcademy, Kristina Lindemann, 340826
SLN vulva update
ESGO eAcademy, Maaike Oonk, 340818
New options of therapy in patients resistant to PARPi
ESGO eAcademy, David Tan, 340832
Role of palliative surgery in ovarian cancer
ESGO eAcademy, Jalid Sehouli, 340825
SLN ultrastaging and management of ITC in uterine cancer
ESGO eAcademy, Nadeem R. Abu-Rustum, 340817
«
...
11
12
13
14
15
16
17
18
19
...
»